Drd2 biased agonist prevents neurodegeneration against NLRP3 inflammasome in Parkinson’s disease model via a β-arrestin2-biased mechanism
- 27 August 2020
- journal article
- research article
- Published by Elsevier BV in Brain, Behavior, and Immunity
- Vol. 90, 259-271
- https://doi.org/10.1016/j.bbi.2020.08.025
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- Control of autoimmune CNS inflammation by astrocytesSeminars in Immunopathology, 2015
- β-Arrestin1–Biased β 1 -Adrenergic Receptor Signaling Regulates MicroRNA ProcessingCirculation Research, 2014
- Structural Features for Functional Selectivity at Serotonin ReceptorsScience, 2013
- Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallinNature, 2012
- Structure–Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor AgonistsJournal of Medicinal Chemistry, 2012
- Discovery of β-Arrestin–Biased Dopamine D 2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic EfficacyProceedings of the National Academy of Sciences of the United States of America, 2011
- Agonist-Biased Signaling at the Histamine H4 Receptor: JNJ7777120 Recruits β-Arrestin without Activating G ProteinsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac PerformanceJournal of Pharmacology and Experimental Therapeutics, 2010
- Interleukin-1β (IL-1β) Processing PathwayScience Signaling, 2010
- β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivationProceedings of the National Academy of Sciences of the United States of America, 2008